EGFR and non-small cell lung carcinoma: On the other hand, Amivantamab, a bispecific antibody targeting MET and EGFR, has been approved by the U.S. Food and Drug Administration (FDA) for the first-line setting and for the treatment of NSCLC patients with one of the two common EGFR mutations who have progressed on osimertinib[73].